Press Releases
Samsung Biologics IPO, Finance Asia Wins 3 awards including ‘Best IPO’
Samsung Biologics IPO, Finance Asia Wins 3 awards including ‘Best IPO’
|
Samsung Biologics(CEO: Kim Tae-Han) received three awards in the ‘Achievement Awards 2016’ held by FinanceAsia, Asia’s leading financial magazine. The company was evaluated as the most successful IPO in 2016.
Samsung Biologics has been awarded ‘Best IPO’ and ‘Best Equity Deal’, Finance Asia selected among companies of 10 countries in Asia. The company was also awarded ‘Best Korea Deal’.
Finance Asia annually selects and announces the best financial transactions such as mergers, acquisitions, and IPOs conducted in Asian countries including China, Hong Kong, and Korea.
Finance Asia said, “Samsung Biologics has secured seven times more sub ions than its IPO size by putting confidence in the investment through global road shows even in the circumstances of Korean companies postponing or cancelling IPOs and changing the US president. It successfully completed the second largest IPO in Korea under this unstable circumstances and that is why we chose the company as the ‘Best IPO”.
After it first announced the listing on the KOSPI market in April, Samsung Biologics has been successfully listed in KOSPI market in November 10th through domestic and foreign investor recruitment. Its IPO recorded many records in the domestic and overseas IPO history.
Samsung Biologics’IPO is the second largest in global bio sector after the US Company Genentech which was listed in 1999 and the second largest in global health care sector after Australian company, Healthscope which was listed in 2014.
Not only that, it is the sixth largest in the world, the third largest in Asia among the last year’s IPO, and the second largest in Korea after Samsung Life(4.9 trillion won), and it is the highest in non-financial sector.
On the other hand, Samsung Biologics was awarded ‘Best Asia CMO’ award at the ‘Biologics manufacturing Asia 2017’ conference held in Singapore on the 15th recognizing its quality and speed competitiveness, and leading the innovation of the biopharmaceutical industry.
- The End-
Samsung Biologics IPO, Finance Asia Wins 3 awards including ‘Best IPO’
|
Samsung Biologics(CEO: Kim Tae-Han) received three awards in the ‘Achievement Awards 2016’ held by FinanceAsia, Asia’s leading financial magazine. The company was evaluated as the most successful IPO in 2016.
Samsung Biologics has been awarded ‘Best IPO’ and ‘Best Equity Deal’, Finance Asia selected among companies of 10 countries in Asia. The company was also awarded ‘Best Korea Deal’.
Finance Asia annually selects and announces the best financial transactions such as mergers, acquisitions, and IPOs conducted in Asian countries including China, Hong Kong, and Korea.
Finance Asia said, “Samsung Biologics has secured seven times more sub ions than its IPO size by putting confidence in the investment through global road shows even in the circumstances of Korean companies postponing or cancelling IPOs and changing the US president. It successfully completed the second largest IPO in Korea under this unstable circumstances and that is why we chose the company as the ‘Best IPO”.
After it first announced the listing on the KOSPI market in April, Samsung Biologics has been successfully listed in KOSPI market in November 10th through domestic and foreign investor recruitment. Its IPO recorded many records in the domestic and overseas IPO history.
Samsung Biologics’IPO is the second largest in global bio sector after the US Company Genentech which was listed in 1999 and the second largest in global health care sector after Australian company, Healthscope which was listed in 2014.
Not only that, it is the sixth largest in the world, the third largest in Asia among the last year’s IPO, and the second largest in Korea after Samsung Life(4.9 trillion won), and it is the highest in non-financial sector.
On the other hand, Samsung Biologics was awarded ‘Best Asia CMO’ award at the ‘Biologics manufacturing Asia 2017’ conference held in Singapore on the 15th recognizing its quality and speed competitiveness, and leading the innovation of the biopharmaceutical industry.
- The End-